Archive | November, 2009

Ligand Pfizer Collaboration Extended (NASDAQ:LGND)

6 November 2009 – 7:30 am PST

Comments Off

Ligand Pfizer Collaboration Extended (NASDAQ:LGND)

Ligand Pharmaceuticals Inc (NASDAQ:LGND) has announced that they have extended their research collaboration with Pfizer for JAK3 by one year.

Continue reading...

Pro-Pharmaceuticals Private Placement (OTC:PRWP)

5 November 2009 – 8:45 am PST

Comments Off

Pro-Pharmaceuticals Private Placement (OTC:PRWP)

Pro-Pharmaceuticals, Inc. (OTC:PRWP) has announced that they have closed a US$310,000 tranche of a private placement for up to US$6.0 million with 10X Fund, L.P. which is purchasing their unregistered Series B convertible preferred stocks and warrants.

Continue reading...

MabCure Signs Research Agreement (OTC:MBCI)

5 November 2009 – 8:16 am PST

View Comments

MabCure Signs Research Agreement (OTC:MBCI)

MabCure N.V., a subsidiary of MabCure Inc (OTC:MBCI) today announced that they have signed a research agreement with AZ Sint Lucas Hospital in Belgium to conduct preclinical research on its monoclonal antibodies against different cancers. Currently, the company’s monoclonal antibodies for the diagnosis of ovarian cancer, prostrate cancer, and colorectal cancer are aimed at diagnosing [...]

Continue reading...

Enzo Biochem at Bio-Europe 2009 (NYSE:ENZ)

5 November 2009 – 8:00 am PST

Comments Off

Enzo Biochem at Bio-Europe 2009 (NYSE:ENZ)

Speaking at the Bio-Europe 2009 Conference in Austria, Enzo Biochem, Inc (NYSE:ENZ) announced that the Company’s therapeutic platforms are utilizing oral immune regulation for immune mediated diseases.

Continue reading...

Covidien and Nuvo Research FDA action date set for today (NYSE:COV, PINK:NRIFF)

4 November 2009 – 11:21 am PST

View Comments

Covidien and Nuvo Research FDA action date set for today (NYSE:COV, PINK:NRIFF)

Covidien (NYSE: COV), a leading global provider of healthcare products, and Nuvo Research Inc. (PINK: NRIFF), a Canadian drug development company, both have an action date of today 11/4/2009 from the Food and Drug Administration (FDA) under the Prescription Drug User Fee Act (PDUFA) for their drug Pennsaid (diclofenac sodium) topical solution 1.5%.

Continue reading...

Teaching Children What Money is All About

4 November 2009 – 7:00 am PST

View Comments

Teaching Children What Money is All About

Most kids have no conception of money. And why should they? Mom or Dad whips out the credit card or debit card to pay for groceries, writes a check to pay the car payment, and goes online to pay the mortgage. When cash is required it means a trip to the ATM machine and then [...]

Continue reading...

Omnicare Finalized Settlement Agreement (NYSE:OCR)

4 November 2009 – 6:00 am PST

Comments Off

Omnicare Finalized Settlement Agreement (NYSE:OCR)

Omnicare, Inc. (NYSE:OCR) have announced today that they have gone ahead and finalized the previously disclosed agreement for a voluntary civil settlement with the US Attorney’s Office, District of Massachusetts, the Department of Justice and Health and Human Services, as well as various of the states in which the Company runs its business.

Continue reading...

UNDT’s Black Mold Detection (OTC:UNDT)

4 November 2009 – 4:30 am PST

Comments Off

UNDT’s Black Mold Detection (OTC:UNDT)

Universal Detection Technology (OTC:UNDT) has announced that they are expanding their product catalogue which will now include a consumer ready kit for the detection of black mold.

Continue reading...

RXi’s Therapeutic Platform (NASDAQ:RXII)

4 November 2009 – 4:00 am PST

Comments Off

RXi’s Therapeutic Platform (NASDAQ:RXII)

RXi Pharmaceuticals Corporation (NASDAQ:RXII) announced that their Vice President of Technology Development, Dmitry Samarsky will be presenting their new RNAi technology development at the Discovery on Target scientific conference in Boston on November 4, 2009.

Continue reading...

Gilead Sciences Combination Therapy (NASDAQ:GILD)

3 November 2009 – 7:45 am PST

Comments Off

Gilead Sciences Combination Therapy (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) in partnership with the GlaxoSmithKline plc (ADR) (NYSE:GSK) today has announced their plans for an international clinical trial to study the combination therapy versus monotherapy in a first-line treatment setting for pulmonary arterial hypertension (PAH).

Continue reading...